{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:26:46Z","timestamp":1789712806279,"version":"4.0.1"},"reference-count":28,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2006,11,13]],"date-time":"2006-11-13T00:00:00Z","timestamp":1163376000000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Among HIV\u2010infected patients, hepatitis C virus (HCV) coinfection is associated with increased rates of lipodystrophy and insulin resistance. Its impact on HIV\u2010associated dyslipidaemia is less clear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The lipid profiles of all HIV\u2010infected patients and a subset of HCV\u2010infected patients seen at the VA Medical Center in Dallas from January 2003 to March 2004 were analysed. Demographic data, HCV serostatus, and HIV treatment history were recorded. Lipid profiles of HIV\/HCV\u2010coinfected patients were compared with those of HIV\u2010monoinfected and HCV\u2010monoinfected patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 359 HIV\u2010infected patients, 91 (25.3%) of whom were HCV coinfected, and 112 HCV\u2010infected patients were included in the analysis. Among the HIV\u2010infected patients, HCV coinfection was associated with a reduced risk of hypercholesterolaemia [9.9% vs 24.8%; relative risk (RR)=0.333; 95% confidence interval (CI)=0.158\u20130.699; <jats:italic>P<\/jats:italic>&lt;0.001] and hypertriglyceridaemia (48.4% vs 60.3%; RR=0.616; 95% CI=0.382\u20130.994; <jats:italic>P<\/jats:italic>=0.031). After controlling for duration of protease inhibitor (PI) therapy, race, alanine aminotransferase (ALT) concentration and platelet count, HCV remained an independent predictor of hypercholesterolaemia (RR=0.369; <jats:italic>P<\/jats:italic>=0.01) and any dyslipidaemia (RR=0.531; <jats:italic>P<\/jats:italic>=0.019). In addition, the rate of dyslipidaemias was lower among HCV\u2010monoinfected than HIV\/HCV\u2010coinfected patients (29.5% vs 50.5; <jats:italic>P<\/jats:italic>=0.002). White race was also an independent predictor of dyslipidaemia (73.8% vs 50.7%; RR=2.32; 95% CI=1.44\u20133.76; <jats:italic>P<\/jats:italic>=0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>HCV coinfection independently predicted lower rates of dyslipidaemia among HIV\u2010infected patients. An analysis of lipid kinetics among mono\u2010 and coinfected patients may elucidate the mechanisms of the apparent protective effect of HCV infection.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2006.00416.x","type":"journal-article","created":{"date-parts":[[2006,11,13]],"date-time":"2006-11-13T10:26:33Z","timestamp":1163413593000},"page":"530-536","source":"Crossref","is-referenced-by-count":25,"title":["Lipid abnormalities in HIV\/hepatitis C virus\u2010coinfected patients"],"prefix":"10.1111","volume":"7","author":[{"given":"R","family":"Bedimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Ghurani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Nsuami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u2010B","family":"Kvanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,11,13]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/319747"},{"key":"e_1_2_5_4_2","first-page":"831","article-title":"Hepatitis C virus prevalence among patients infected with human immunodeficiency virus","volume":"34","author":"Sherman KE","year":"2002","journal-title":"a cross-sectional analysis of the US adult AIDS Clinical Trials Group"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908193410802"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_5_7_2","first-page":"174","article-title":"The prevalence of lipodystrophy in an ambulant HIV\u2010infected population","volume":"2","author":"Carter VM","year":"2001","journal-title":"it all depends on the definition"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200108150-00004"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00058.2002"},{"key":"e_1_2_5_10_2","first-page":"59","article-title":"Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy","volume":"15","author":"Balasubramanyam A","year":"2004","journal-title":"a model of \u2018systemic steatosis\u2019"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jurban\/jtg074"},{"key":"e_1_2_5_12_2","first-page":"121","article-title":"Causes of death among human immunodeficiency virus (HIV)\u2010infected adults in the era of potent antiretroviral therapy","volume":"34","author":"Lewden C","year":"2005","journal-title":"emerging role of hepatitis and cancers, persistent role of AIDS"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/343862"},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00126334-200107010-00005","article-title":"Association between insulin resistance and hepatitis C virus chronic infection in HIV\u2010hepatitis C virus\u2010coinfected patients undergoing antiretroviral therapy","volume":"27","author":"Duong M","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200303010-00018"},{"key":"e_1_2_5_16_2","first-page":"927","article-title":"Hyperlipidemia in HIV\u2010infected patients","volume":"17","author":"Collazos J","year":"2003","journal-title":"the protective effect of hepatitis C virus co-infection"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200405010-00015"},{"key":"e_1_2_5_18_2","first-page":"451","article-title":"Effect of highly active antiretroviral therapy (HAART) and hepatitis C co\u2010infection on hyperlipidemia in HIV\u2010infected patients","volume":"3","author":"Patroni A","year":"2002","journal-title":"a retrospective longitudinal study"},{"key":"e_1_2_5_19_2","first-page":"800","article-title":"Lipid disorders in antiretroviral\u2010naive patients treated with lopinavir\/ritonavir\u2010based HAART","volume":"55","author":"Montes ML","year":"2005","journal-title":"frequency, characterization and risk factors"},{"key":"e_1_2_5_20_2","first-page":"79","article-title":"Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV\u2010infected patients","volume":"6","author":"Richter A","year":"2005","journal-title":"a retrospective cohort study"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200307040-00011"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2004.00202.x"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2003.06.002"},{"issue":"1","key":"e_1_2_5_24_2","first-page":"S141","article-title":"HIV lipodystrophy","volume":"17","author":"Carr A.","year":"2003","journal-title":"risk factors, pathogenesis, diagnosis and management"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200301010-00007"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1310\/VHBA-X9FE-YRQR-YVBK"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.12.1313"},{"key":"e_1_2_5_28_2","first-page":"56","article-title":"Serum lipid pattern in chronic hepatitis C","volume":"13","author":"Siagris D","year":"2006","journal-title":"histological and virological correlations"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-864785"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2006.00416.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2006.00416.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T17:58:29Z","timestamp":1696960709000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2006.00416.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1111\/j.1468-1293.2006.00416.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2006.00416.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}